Menu

Markets

Research

News

Learn

AI Chat
Get the app WatchlistsPortfoliosAlerts
Pricing Sign in

Stevanato Group S.p.A. STVN

Full chart Compare
Set alert

Price alert · STVN

All alert types
13.31 USD -0.43 (-3.10%)

Nov 10, 2026, 1:15 PM EST

13.25 Day range 13.95
12.05 52-week range 25.45
YTD
-33.87%
1 year
-45.13%
Market cap
3.62B
Revenue (ttm)
1.25B
Profit margin
11.25%
EPS (ttm)
0.59
Shares out
49.83M
P/E ratio
22.47
Forward P/E
18.85
Dividend
0.06
Ex-dividend date
Jun 10, 2026
YTD return
-33.87%
1-year return
-45.13%
Volume
191.15K
Avg volume
603.99K
Open
13.56
Previous close
13.73
Day's range
13.25 – 13.95
52-week range
12.05 – 25.45
Beta
0.80
Analysts
Buy
Price target
19.46 (+46.2%)
Earnings date
Mar 3, 2027
1D5D1M3M6MYTD1Y2Y5YMAXALL
Customize chart

5D -0.36 (-2.62%)

1314WedThuFriMonTue13.37

Key statistics

Financials
Enterprise value
4.06B
PEG ratio
1.68
Price / sales
2.99
Price / book
2.08
Dividend yield
0.45%
Payout ratio
10.59%
Revenue growth
7.60%
Free cash flow
-65.24M
Total cash
116.02M
Total debt
471.43M
Return on equity
9.26%
Short % of float
1.97%
50-day average
19.81
200-day average
17.98

Analyst view

Consensus: buy

Buy
Price target (mean) 19.46 +46.2% upside
Target (low)
16.00
Target (mean)
19.46
Target (high)
25.00
Ratings (0m) 13 9 buy · 4 hold · 0 sell
  • Strong buy3
  • Buy6
  • Hold4
  • Sell0
  • Strong sell0

Next earnings

Mar 3, 2027

Expected Mar 3, 2027. Consensus EPS estimate 0.22591.

Earnings history

Financials — quick view

All financials
STVN Revenue — quarterly 326.06M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
STVN Net income — quarterly 41.84M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
STVN EPS — quarterly 0.15
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

STVN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 3, 2027Dec 30, 20260.21———
Nov 3, 2026Sep 30, 20260.17750.180.00+1.41%
Aug 4, 2026Jun 30, 20260.14480.16+0.02+10.50%
May 7, 2026Mar 31, 20260.120.13+0.01+8.33%
Mar 4, 2026Dec 31, 20250.200.21+0.01+5.00%
Nov 6, 2025Sep 30, 20250.140.16+0.02+14.29%

Upgrades / downgrades

STVN analyst upgrades and downgrades
DateFirmActionFromTo
Nov 4, 2026William BlairdownOutperformMarket Perform
Nov 4, 2026UBSmainNeutralNeutral
Nov 4, 2026CitigroupmainBuyBuy
Sep 9, 2026UBSmainNeutralNeutral
Jun 16, 2026TD Coweninit—Buy
Mar 6, 2026Morgan StanleymainEqual-WeightEqual-Weight

About Stevanato Group S.p.A.

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
Italy
Website
stevanatogroup.com

News

All news

Your note

Sign in to keep a note on STVN — it syncs with the Stock Master app.

Insider holders

STVN insider holders
InsiderRelationLatest transactionDateShares held
BALACHANDRAN MADHAVENDirectorSaleJun 14, 202669,458
DAL LAGO MARCOChief Financial OfficerSaleAug 6, 202681,144
FEDERICI WILLIAM JDirectorSaleJun 14, 202658,580
FLYNN KAREN ADirectorSaleJun 14, 20265,757
LIN SUE-JEANDirectorStock Award(Grant)Jun 11, 20266,975
MAGISTRETTI ELISABETTADirectorSaleAug 6, 20262,930

Institution ownership

STVN institution ownership
Holder% heldSharesValueReported
Neuberger Berman Group, LLC1.86%5,622,26976.80MJun 29, 2026
Conestoga Capital Advisors, LLC1.85%5,596,51576.45MSep 29, 2026
Times Square Capital Management, LLC1.07%3,252,89944.43MSep 29, 2026
Van Berkom & Associates Inc.0.94%2,858,32339.04MSep 29, 2026
Artisan Partners Limited Partnership0.86%2,601,59835.54MJun 29, 2026
BAMCO Inc.0.82%2,494,87134.08MJun 29, 2026

Fund ownership

STVN fund ownership
Holder% heldSharesValueReported
Conestoga Funds-Conestoga Small Cap Fund1.15%3,484,75147.60MJun 29, 2026
NEUBERGER BERMAN EQUITY FUNDS-Neuberger Genesis Fund1.00%3,041,14141.54MSep 29, 2026
BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd.0.56%1,681,42922.97MJun 29, 2026
American Century Mutual Funds, Inc.-Small Cap Growth Fund0.32%977,76513.36MSep 29, 2026
Artisan Partners Funds Inc.-Artisan Small Cap Fund0.28%837,77311.44MJun 29, 2026
AMG Funds-AMG TimesSquare Mid Cap Growth Fund0.22%653,1378.92MJun 29, 2026

Dividends

STVN recent dividends
Ex-dividend dateAmount
Jun 11, 20260.0622
Jun 5, 20250.0618
Jun 4, 20240.058
Jun 7, 20230.057769
Jun 13, 20220.051